DKY709

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Carcinoma, Non-Small-Cell LungDifferent types of advanced cancerMelanomaMicrosatellite Stable Colorectal CancerNasopharyngeal CarcinomaTriple Negative Breast Cancer

Phase 1

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Active, not recruitingNCT03891953

Novartis PharmaceuticalsCarcinoma, Non-Small-Cell Lung, Melanoma, Microsatellite Stable Colorectal Cancer +2

Start: 2019-05-07End: 2026-10-31Updated: 2026-01-21

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

Active, not recruitingCTIS2023-508841-42-00

Novartis Pharma AGDifferent types of advanced cancer

Start: 2019-10-30Target: 75Updated: 2025-10-28